A Study of Duration of Maintained Efficacy in Rheumatoid Arthritis (RA) Patients Off Treatment With MRA(a Development Code of Tocilizumab, an Anti IL-6 Receptor Monoclonal Antibody.)
NCT ID: NCT00661284
Last Updated: 2012-08-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
189 participants
OBSERVATIONAL
2008-04-30
2010-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
PhaseⅢOpen-label Study of MRA for Rheumatoid Arthritis(RA)
NCT00380601
Study of MRA in Patients With Rheumatoid Arthritis (RA)
NCT00144651
Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA213JP
NCT00144534
Success of Tocilizumab in RA Patients With Remission Induction and Sustained Efficacy After Discontinuation
NCT01120366
Phase III Comparative Study(Open-Label) of MRA for Rheumatoid Arthritis(RA)
NCT00144508
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ⅰ
Subject who have participated in previous studies and achieved DAS28 of \< 3.2 at the last observation and at least one time point among the two previous assessment time points in a previous studies.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chugai Pharmaceutical
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yuji Kimura
Role: STUDY_CHAIR
Chugai Pharmaceutical,Clinical Research Department 1
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chugoku region
Chugoku, , Japan
Kanto region
Kanto, , Japan
Kyushu region
Kyushu, , Japan
Sikoku region
Sikoku, , Japan
Tohoku region
Tōhoku, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MRA226JP
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.